This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Dec;4(12):648-9.

doi: 10.1038/ncpcardio1030. Epub 2007 Oct 9.

Is rosiglitazone associated with increased risk for cardiovascular events?

Markolf Hanefeld¹

Affiliations

PMID: 17925798
DOI: 10.1038/ncpcardio1030

Comment

Is rosiglitazone associated with increased risk for cardiovascular events?

Markolf Hanefeld. Nat Clin Pract Cardiovasc Med. 2007 Dec.

. 2007 Dec;4(12):648-9.

doi: 10.1038/ncpcardio1030. Epub 2007 Oct 9.

Author

Markolf Hanefeld¹

Affiliation

¹ Centre for Clinical Studies at the Technical University in Dresden, Germany. hanefeld@gwtonline-zks.de

PMID: 17925798
DOI: 10.1038/ncpcardio1030

No abstract available

PubMed Disclaimer

Comment on

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Nissen SE, Wolski K. Nissen SE, et al. N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21. N Engl J Med. 2007. PMID: 17517853

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.